Research Tracker›Biomarker Atlas›Marker Pages›Gut microbiome alpha diversity

Gut microbiome alpha diversity: biomarker evidence

Gut microbiome alpha diversity appears in 1 entry of the OSMF biomarker atlas, covering Long COVID. Across those entries it is reduced in 1. It is currently reported in a single condition in this atlas; cross-condition comparison will be added as the dataset grows. Each row below links to a page with the comparison group, associated symptoms, test details and primary citation.

Long COVID

Where Gut microbiome alpha diversity is reported

Also listed as: Shannon index

ConditionDirectionCompared againstAssociated symptomsSource
Long COVID↓ reducedhealthy controlsGI symptoms, dysbiosisBaalbaki et al. 2025

Frequently asked questions

In which conditions is Gut microbiome alpha diversity altered?

In the OSMF atlas Gut microbiome alpha diversity is reported in Long COVID. It is reduced in 1 across 1 entries.

Is there a standard clinical test for Gut microbiome alpha diversity?

The atlas entries for Gut microbiome alpha diversity do not carry a LOINC code, which usually means the marker was measured with research assays or study-specific methods rather than a routine clinical panel.

Is one abnormal Gut microbiome alpha diversity result diagnostic?

No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.

Cite this page

Open Source Medicine Foundation. (2026). Gut microbiome alpha diversity across conditions: biomarker evidence. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/markers/gut-microbiome-alpha-diversity.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-29 · Browse: Biomarker Index · All marker pages · Biomarker Atlas

Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.